{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:37:19Z","timestamp":1793356639331,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"SK Life Science, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40268-020-00305-4","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T23:06:11Z","timestamp":1587683171000},"page":"125-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["An Ex Vivo Evaluation of Cenobamate Administered via Enteral Tubes"],"prefix":"10.1007","volume":"20","author":[{"given":"Louis","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkady","family":"Nisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Pegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Ursino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"305_CR1","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.2146\/ajhp080155","volume":"65","author":"NT Williams","year":"2008","unstructured":"Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65:2347\u201357.","journal-title":"Am J Health Syst Pharm"},{"key":"305_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.yebeh.2017.06.024","volume":"74","author":"C Jory","year":"2017","unstructured":"Jory C, et al. Going down the tubes! Impact on seizure control of antiepileptic medication given via percutaneous feeding tubes. Epilepsy Behav. 2017;74:114\u20138.","journal-title":"Epilepsy Behav"},{"key":"305_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.20960\/nh.486","volume":"34","author":"MPP Beserra","year":"2017","unstructured":"Beserra MPP, et al. Drugs via enteral feeding tubes in inpatients: dispersion analysis and safe use of dispensers. Nutr Hosp. 2017;34:257\u201363.","journal-title":"Nutr Hosp"},{"key":"305_CR4","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1177\/0018578717732340","volume":"52","author":"K Reindel","year":"2017","unstructured":"Reindel K, et al. In vitro evaluation of eslicarbazepine delivery via enteral feeding tubes. Hosp Pharm. 2017;52:752\u201360.","journal-title":"Hosp Pharm"},{"key":"305_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cpdd.123","volume":"3","author":"KT Moore","year":"2014","unstructured":"Moore KT, et al. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Clin Pharmacol Drug Dev. 2014;3:321\u20137.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"305_CR6","unstructured":"US Food and Drug Administration. FDA approves new treatment for adults with partial-onset seizures [press release]. 2019 November 21 [cited 2019 December 6]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-adults-partial-onset-seizures. Accessed Jan 4, 2020."},{"key":"305_CR7","doi-asserted-by":"crossref","unstructured":"Chung SS, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2019 (in press).","DOI":"10.1212\/WNL.0000000000009530"},{"key":"305_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, et al. Efficacy and safety of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicenter, double-blind, randomized, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38\u201348.","journal-title":"Lancet Neurol"},{"key":"305_CR9","doi-asserted-by":"crossref","unstructured":"Sperling M, Klein P, Kamin M. Safety of cenobamate (YKP3089) as adjunctive treatment for uncontrolled partial seizures in a large, multicenter, open-label study [abstract]. In: American Epilepsy Society Annual Meeting, November 30\u2013December 4, 2018, New Orleans, Abstract 1.303.","DOI":"10.1212\/WNL.92.15_supplement.P1.5-019"},{"key":"305_CR10","unstructured":"XCOPRI\u00ae (cenobamate tablets), for oral use, CV [prescribing information]. Paramus: SK Life Science, Inc.; 2020."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-020-00305-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-020-00305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T16:09:07Z","timestamp":1722787747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-020-00305-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1007\/s40268-020-00305-4","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"23 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"LF: employee of SK Life Science, Inc. AN: employee of SK Life Science, Inc. AP: employee of SK Life Science, Inc. JU: employee of SK Life Science, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript was funded, in part, by SK Life Science, Inc. The study was funded by SK Life Science, Inc (Fair Lawn, NJ). The Open Access fee was paid for by SK Life Science, Inc. Professional medical writing assistance and editorial assistance, funded by SK Life Science, Inc, were provided by Dorothy McCoy, PharmD, BCPS BCIDP, of MedVal Scientific Information Services, LLC (Princeton, NJ). This manuscript was prepared according to the International Society for Medical Publication Professionals\u2019 \u201cGood Publication Practice for Communicating Company-Sponsored Medical Research: The GPP3 Guidelines.\u201d","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}